Last reviewed · How we verify

NCT04103359: FITME

Comparison of Lower-risk MDS Patients With and Without Improvements in Fatigue Following Blood Transfusion Therapy

Terminated NA Last updated 6 May 2023
What this trial tests

NA trial testing Physiological tests to measure fatigue level in Myelodysplatic Syndromes in 1 participant. Terminated before completion.

Timeline
20 October 2020
Primary endpoint
20 October 2020
20 October 2020

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Saint Etienne
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment1
Start date20 October 2020
Primary completion20 October 2020
Estimated completion20 October 2020
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Who can join

18 and older, any sex, with Myelodysplatic Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

At present, it is unclear why some myelodysplastic patients (MDS) receiving blood transfusion therapy exhibit an increase in Hemoglobin (Hb) without a concurrent improvement in fatigue. Research is thus required to elucidate on why fatigue persists in some MDS patients in order to devise strategies to alleviate fatigue in "non-responders" to blood transfusion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Centre Hospitalier Universitaire de Saint Etienne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04103359.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing